Published in PLoS One on August 31, 2017
Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science (2005) 39.06
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet (2010) 10.79
Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol (2009) 6.68
Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants. Clin Cancer Res (2011) 4.65
Androgen receptor signaling in androgen-refractory prostate cancer. J Natl Cancer Inst (2001) 3.06
Characterization of a novel androgen receptor mutation in a relapsed CWR22 prostate cancer xenograft and cell line. Cancer Res (2002) 2.99
Establishment and characterization of androgen-independent human prostate cancer LNCaP cell model. Prostate (2002) 2.05
Androgen receptor signaling in prostate cancer development and progression. J Carcinog (2011) 1.90
The role of the androgen receptor in the development and progression of prostate cancer. Semin Oncol (1999) 1.65
ETV1 is a novel androgen receptor-regulated gene that mediates prostate cancer cell invasion. Mol Endocrinol (2007) 1.32
Regulation of nitric oxide and soluble guanylyl cyclase. Brain Res Bull (2004) 1.30
Arginine containing peptides as delivery vectors. Adv Drug Deliv Rev (2003) 1.25
Microarray coupled to quantitative RT-PCR analysis of androgen-regulated genes in human LNCaP prostate cancer cells. Oncogene (2009) 1.16
Anticancer activity of a novel selective CYP17A1 inhibitor in preclinical models of castrate-resistant prostate cancer. Mol Cancer Ther (2014) 1.08
Dimerization region of soluble guanylate cyclase characterized by bimolecular fluorescence complementation in vivo. Mol Pharmacol (2007) 1.04
Casein kinase: the triple meaning of a misnomer. Biochem J (2014) 1.00
Mechanisms of persistent activation of the androgen receptor in CRPC: recent advances and future perspectives. World J Urol (2011) 0.99
Androgen induces expression of the multidrug resistance protein gene MRP4 in prostate cancer cells. Prostate Cancer Prostatic Dis (2006) 0.94
Hormonal regulation of prostate-specific antigen (PSA) glycoprotein in the human prostatic adenocarcinoma cell line, LNCaP. Prostate (1992) 0.93
Androgen regulation of soluble guanylyl cyclasealpha1 mediates prostate cancer cell proliferation. Oncogene (2006) 0.93
Strigolactone analogues induce apoptosis through activation of p38 and the stress response pathway in cancer cell lines and in conditionally reprogrammed primary prostate cancer cells. Oncotarget (2014) 0.90
Soluble guanylyl cyclase α1 and p53 cytoplasmic sequestration and down-regulation in prostate cancer. Mol Endocrinol (2011) 0.90
Targeting persistent androgen receptor signaling in castration-resistant prostate cancer. Med Oncol (2016) 0.85
A peptide against soluble guanylyl cyclase α1: a new approach to treating prostate cancer. PLoS One (2013) 0.83
Human kallikrein 2 (KLK2) promotes prostate cancer cell growth via function as a modulator to promote the ARA70-enhanced androgen receptor transactivation. Tumour Biol (2014) 0.81
TM4SF3 and AR: A Nuclear Complex that Stabilizes Both Proteins. Mol Endocrinol (2015) 0.79
Ferroptosis: a novel cell death form will be a promising therapy target for diseases. Acta Biochim Biophys Sin (Shanghai) (2015) 0.77
COP9 subunits 4 and 5 target soluble guanylyl cyclase α1 and p53 in prostate cancer cells. Mol Endocrinol (2014) 0.76
Zinc Finger 280B regulates sGCα1 and p53 in prostate cancer cells. PLoS One (2013) 0.86
A peptide against soluble guanylyl cyclase α1: a new approach to treating prostate cancer. PLoS One (2013) 0.83